Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study

被引：8

作者：

Elman, Lauren ^{[1
]}

Youn, Bora ^{[2
]}

Proud, Crystal M. ^{[3
]}

Frey, Margaret R. ^{[4
]}

Ajroud-Driss, Senda ^{[5
]}

McCormick, M. Eileen ^{[6
]}

Michelson, David ^{[7
]}

Cartwright, Michael S. ^{[8
]}

Heiman-Patterson, Terry ^{[9
]}

Choi, Joseph M. ^{[10
]}

Chandak, Aastha ^{[11
]}

Khachatryan, Artak ^{[12
]}

Martinez, Marta ^{[12
]}

Paradis, Angela D. ^{[2
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Biogen, Cambridge, MA USA

[3] Childrens Hosp Kings Daughters, Norfolk, VA USA

[4] Mem Healthcare Inst Neurosci, Owosso, MI USA

[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[6] Oakland Univ, William Beaumont Sch Med, Royal Oak, MI USA

[7] Loma Linda Univ Hlth, Loma Linda, CA USA

[8] Wake Forest Sch Med, Winston Salem, NC 27101 USA

[9] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA

[10] Georgetown Univ Hosp, Washington, DC 20007 USA

[11] Certara, New York, NY USA

[12] Certara, London, England

来源：

JOURNAL OF NEUROMUSCULAR DISEASES | 2022年 / 9卷 / 05期

关键词：

Medication adherence; spinal muscular atrophy; antisense oligonucleotides; neuromuscular diseases; retrospective studies; adults; SHAM CONTROL;

D O I：

10.3233/JND-210768

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Limited evidence exists on real-world adherence to nusinersen for the treatment of spinal muscular atrophy (SMA). Data are presented from a multi-site retrospective chart review of 86 adults with SMA initiating nusinersen at nine US centers between January 2017 and February 2019. Seventy-nine (92%) adults remained on nusinersen during the study; 454 (92%) of 493 total nusinersen doses were received on time. Fifty-eight (67%) adults received all nusinersen doses on time. The majority of patients with at least one nonadherent dose resumed nusinersen on time. Most patients followed the dosing schedule across the loading and maintenance dose periods.

引用

页码：655 / 660

页数：6

共 50 条

[21] Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis
Fox, David
To, Tu My
Seetasith, Arpamas
Patel, Anisha M.
Iannaccone, Susan T.
ADVANCES IN THERAPY, 2023, 40 (03) : 903 - 919
[22] Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis
David Fox
Tu My To
Arpamas Seetasith
Anisha M. Patel
Susan T. Iannaccone
Advances in Therapy, 2023, 40 : 903 - 919
[23] Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy
Yeo, Crystal Jing Jing
Simeone, Sarah D.
Townsend, Elise L.
Zhang, Ren Zhe
Swoboda, Kathryn J.
JOURNAL OF NEUROMUSCULAR DISEASES, 2020, 7 (03) : 257 - 268
[24] REAL-WORLD OUTCOMES AND HEALTH CARE RESOURCE UTILIZATION OF ONASEMNOGENE ABEPARVOVEC FOR US PATIENTS WITH SPINAL MUSCULAR ATROPHY TYPE 2: RESULTS OF A RETROSPECTIVE CHART REVIEW STUDY
Dabbous, O.
Yang, M.
Georgieva, M.
Toro, W.
LaMarca, N.
Patel, A.
Anderson, A.
Reyna, S. P.
VALUE IN HEALTH, 2022, 25 (12) : S441 - S441
[25] Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience
Lusakowska, Anna
Wojcik, Adrianna
Fraczek, Anna
Aragon-Gawinska, Karolina
Potulska-Chromik, Anna
Baranowski, Pawel
Nowak, Ryszard
Rosiak, Grzegorz
Milczarek, Krzysztof
Konecki, Dariusz
Gierlak-Wojcicka, Zuzanna
Burlewicz, Malgorzata
Kostera-Pruszczyk, Anna
ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
[26] A National Spinal Muscular Atrophy Registry for Real-World Evidence
Hodgkinson, Victoria L.
Oskoui, Maryam
Lounsberry, Joshua
M'Dahoma, Said
Butler, Emily
Campbell, Craig
MacKenzie, Alex
McMillan, Hugh J.
Simard, Louise
Vajsar, Jiri
Brais, Bernard
Chapman, Kristine M.
Chrestian, Nicolas
Crone, Meghan
Dobrowolski, Peter
Dojeiji, Susan
Dowling, James J.
Dupre, Nicolas
Genge, Angela
Gonorazky, Hernan
Hasal, Simona
Izenberg, Aaron
Johnston, Wendy
Leung, Edward
Lochmuller, Hanns
Mah, Jean K.
Marerro, Alier
Massie, Rami
McAdam, Laura
McCormick, Anna
Melanson, Michel
Mezei, Michelle M.
Nguyen, Cam-Tu E.
O'Connell, Colleen
O'Ferrall, Erin K.
Pfeffer, Gerald
Phan, Cecile
Plamondon, Stephanie
Poulin, Chantal
Rodrigue, Xavier
Schellenberg, Kerri L.
Selby, Kathy
Sheriko, Jordan
Shoesmith, Christen
Smith, Garth
Taillon, Monique
Taylor, Sean
Warman Chardon, Jodi
Worley, Scott
Korngut, Lawrence
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2020, 47 (06) : 810 - 815
[27] Effect of Nusinersen on Respiratory and Bulbar Function in Children with Spinal Muscular Atrophy: Real-World Experience from a Single Center
Gaboli, Mirella
Lobato, Mercedes Lopez
Fernandez, Justo Valverde
Ferri, Patricia Ferrand
Perez, Eloisa Rubio
Ruiz, Henry A. Andrade
Gonzalez, Jose Maria Lopez-Puerta
Madruga-Garrido, Marcos
NEUROPEDIATRICS, 2025, 56 (01) : 2 - 11
[28] Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience
Anna Łusakowska
Adrianna Wójcik
Anna Frączek
Karolina Aragon-Gawińska
Anna Potulska-Chromik
Paweł Baranowski
Ryszard Nowak
Grzegorz Rosiak
Krzysztof Milczarek
Dariusz Konecki
Zuzanna Gierlak-Wójcicka
Małgorzata Burlewicz
Anna Kostera-Pruszczyk
Orphanet Journal of Rare Diseases, 18
[29] Nusinersen treatment in adults with severe spinal muscular atrophy: A real-life retrospective observational cohort study
Lefeuvre, C.
Brisset, M.
Sarlon, M.
Petit, N.
Orlikowski, D.
Clair, B.
Thiry, T.
Carlier, R-Y
Prigent, H.
Nicolas, G.
Annane, D.
Laforet, P.
Pouplin, S.
REVUE NEUROLOGIQUE, 2022, 178 (03) : 234 - 240
[30] Real-world outcomes of disease-modifying treatment for patients with spinal muscular atrophy: findings from a global retrospective chart review
Dabbous, O.
LaMarca, N.
Toro, W.
Wallach, S.
Mumneh, N.
Aassi, M.
O'Brien, E.
Baranello, G.
Reyna, S.
NEUROMUSCULAR DISORDERS, 2023, 33 : S136 - S136

← 1 2 3 4 5 →